What is a stock summary page? Click here for an overview.
Business Description
TG Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US88322Q1085
Share Class Description:
LTS:0VGI: Ordinary SharesDescription
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.23 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 1.14 | |||||
| Debt-to-EBITDA | 5.07 | |||||
| Interest Coverage | 1.74 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 9.25 | |||||
| Beneish M-Score | -1.04 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 242.7 | |||||
| 3-Year FCF Growth Rate | 51.7 | |||||
| 3-Year Book Growth Rate | -4.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 151.62 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 42.72 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.93 | |||||
| 9-Day RSI | 78.53 | |||||
| 14-Day RSI | 77.26 | |||||
| 3-1 Month Momentum % | -0.53 | |||||
| 6-1 Month Momentum % | 29.54 | |||||
| 12-1 Month Momentum % | 110.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.25 | |||||
| Quick Ratio | 5.03 | |||||
| Cash Ratio | 3.43 | |||||
| Days Inventory | 747.19 | |||||
| Days Sales Outstanding | 98.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.8 | |||||
| Shareholder Yield % | -0.99 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.3 | |||||
| Operating Margin % | 12.74 | |||||
| Net Margin % | 7.11 | |||||
| FCF Margin % | -12.32 | |||||
| ROE % | 12.81 | |||||
| ROA % | 5.16 | |||||
| ROIC % | 32.34 | |||||
| 3-Year ROIIC % | 263.03 | |||||
| ROC (Joel Greenblatt) % | 51.85 | |||||
| ROCE % | 13.9 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 299.21 | |||||
| Forward PE Ratio | 40.32 | |||||
| PE Ratio without NRI | 299.21 | |||||
| PS Ratio | 20.02 | |||||
| PB Ratio | 29.36 | |||||
| Price-to-Tangible-Book | 30 | |||||
| EV-to-EBIT | 134.57 | |||||
| EV-to-EBITDA | 133.81 | |||||
| EV-to-Revenue | 20.35 | |||||
| EV-to-Forward-Revenue | 12.4 | |||||
| EV-to-FCF | -160.98 | |||||
| Price-to-GF-Value | 0.24 | |||||
| Price-to-Graham-Number | 20.27 | |||||
| Price-to-Net-Current-Asset-Value | 31.78 | |||||
| Earnings Yield (Greenblatt) % | 0.74 | |||||
| FCF Yield % | -0.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TG Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 329.004 | ||
| EPS (TTM) ($) | 0.14 | ||
| Beta | 4.07 | ||
| 3-Year Sharpe Ratio | 0.79 | ||
| 3-Year Sortino Ratio | 1.64 | ||
| Volatility % | 53.99 | ||
| 14-Day RSI | 77.26 | ||
| 14-Day ATR ($) | 0.393081 | ||
| 20-Day SMA ($) | 34.945 | ||
| 12-1 Month Momentum % | 110.61 | ||
| 52-Week Range ($) | 12.94 - 38.55 | ||
| Shares Outstanding (Mil) | 157.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TG Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TG Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
TG Therapeutics Inc Frequently Asked Questions
What is TG Therapeutics Inc(LTS:0VGI)'s stock price today?
The current price of LTS:0VGI is $37.50. The 52 week high of LTS:0VGI is $38.55 and 52 week low is $12.94.
When is next earnings date of TG Therapeutics Inc(LTS:0VGI)?
The next earnings date of TG Therapeutics Inc(LTS:0VGI) is 2025-05-01 Est..
Does TG Therapeutics Inc(LTS:0VGI) pay dividends? If so, how much?
TG Therapeutics Inc(LTS:0VGI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers